K-ras mutation Liver metastasis Colorectal cancer Codon 13 Micrometastasis K-ras mutation status has remained elusive in the metastatic liver tumors of colorectal cancer (CRC) in contrast to the primary CRC tumors. In this study, K-ras mutational status of the primary and corresponding liver metastatic tumors was investigated in the 43 CRC patients. Codons 12 and 13 of K-ras were directly sequenced, and a K-ras mutation was evident in 17 cases (39.5%). In 6 cases, the K-ras mutation was evident only in the liver metastasis, but not in the primary CRC, where the mutation was found in codon 13. This discrepancy between primary and metastatic lesions with regard to codon 13 of the K-ras gene may explain the clinical discrepancy of EGFR antibody therapy. In conclusion, the current data may lead to the development of personalized medicine for recurrent CRC, although further validation study is still required.
Introduction
K-ras is a critical proto-oncogene involved in signal transduction; it plays a central role in cancer cell proliferation, invasion, and metastasis [1] . Oncogenic K-ras mutations are common in colorectal [2] , pancreatic [3] , and lung cancers [4] ; such mutations transduce oncogenic signals to downstream molecules, including PI3 kinase and MAP kinase [1] . Progress in oncological philosophy indicates that genetic alterations could be targeted for the purpose of clinical cancer control, because they are the most upstream alterations and the bona-fide targets which can explain cancer phenotype [5] .
Colorectal cancer (CRC) is the second most prevalent cancer worldwide [6] , and highly advanced CRC is very difficult to treat [7] . Inhibition of EGFR (epidermal growth factor receptor) via a monoclonal anti-EGFR antibody (e.g., cetuximab) can be an effective treatment for highly advanced CRC, especially for tumors with wild-type K-ras [8] . This inhibition of EGFR through monoclonal anti-EGFR antibody is theoretically reasonable because K-ras functions downstream of and is activated by EGFR. However, monoclonal anti-EGFR antibodies are sometimes ineffective against metastasis derived from CRC even when the primary CRC has wild-type K-ras, which might be due to differences between primary CRCs and the corresponding metastatic tumors with regard to K-ras mutational status.
Some studies of the relationship between K-ras gene mutations and various clinicopathological characteristics have been conducted, but the results remain inconclusive [9] [10] [11] [12] . To clarify the relationship between K-ras gene mutations and the prognosis for patients with colorectal cancer, it was necessary to perform a systematic review and meta-analysis of the published studies to derive a more precise estimation [13] , where the associations of the prognostic significance for patients with mutations at codon 12 become nonsignificant after adjusting for the effect of publication bias, while K-ras mutations at codon 13 are associated with poorer overall survival.
On the other hand, the mutational profiles of K-ras in primary CRCs and corresponding metastatic CRCs have been previously examined in few literatures [14, 15] ; therefore, we investigated the K-ras mutational profiles in order to assess the metastatic significance of K-ras mutation in CRC progression.
Patients and methods

Patients and DNA extraction
Forty three CRC cases involving synchronous (n = 13) or metachronous metastases to the liver (n = 30) were retrospectively analyzed; each tumor (primary or metastatic) was surgically resected. Patient characteristics are listed in Table 1 . Each of the 43 patients underwent surgical resection of both the primary CRC cancer and liver metastasis at the Kitasato University Hospital between 1995 and 2010. QIAamp DNA FFPE Tissue Kits (QIAGEN in Japan Inc., Tokyo) were used to extract DNA from paraffin-embedded and formalin-fixed tissue specimens from primary CRCs and the corresponding liver metastases to investigate K-ras mutational status of each tumor.
Direct sequencing and single-strand conformation polymorphism (SSCP) analysis of the K-ras gene in primary CRCs and each corresponding liver metastasis
The K-ras gene was directly sequenced from each DNA sample to determine the K-ras mutational status of each tumor (n = 86) from each patient (n = 43). Polymerase chain reaction (PCR)-amplified DNA was purified using QIAquick PCR Purification Kits (QIAGEN) that were used to purify PCR-amplified DNA fragments, which were then sent to an outside sequence service, FASMAC Inc. (Kanagawa, Japan), for further processing. GGTGGAGTATTTGATAGTGTATTAACC and AGAA TGGTCCTGCACCAGTAA were used as forward and reverse primers, respectively, to amplify codons 12 and 13 of K-ras, which are the most commonly mutated K-ras codons in CRCs. Another primer, TCATTATT TTTATTATAAGGCCTGCTG, was used for each sequencing reaction to reduce background signal [16] . Non-radioactive SSCP analysis was performed as described previously to screen for mutations in K-ras exon 1, which includes both codons 12 and 13 [2] .
Statistical analysis
The Kaplan-Meier method was used to estimate cumulative 5-year overall survival (OS), and the log rank test was used to assess the significance of between-group differences in OS. OS was measured from the date of liver surgery to that of death or last follow-up. The median observed OS was 35 months (range 4 to 60 months). A value of P b 0.05 was considered statistically significant. JMP, version 10.0 (SAS Institute) was used to perform all statistical analyses.
Results
Direct sequence analysis and K-ras mutational status in primary CRCs and each corresponding liver metastasis
A K-ras mutation was found in the primary CRC, the liver metastasis, or both in 17 (39.5%) of the 43 CRC patients. Among these 17 cases, nine involved a K-ras mutation in both the primary CRC and the liver metastasis; the other eight cases involved a K-ras mutation in only one tumor, either the primary CRC (n = 3) or the liver metastasis (n = 5).
Of the 13 cases of CRC with synchronous liver metastasis, only one (8%) involved a K-ras mutation in both the primary and the metastatic tumor; 8 (27%) of 30 CRC cases with metachronous liver metastasis involved a K-ras mutation in both the primary and the metastatic tumor (P = 0.16) (Fig. 1a) . Among the 8 cases that involved a primary CRC and a corresponding liver metastasis with differing K-ras mutational status, a K-ras mutation was found only in liver metastasis in four cases involving metachronous liver metastasis (Fig. 1b) ; K-ras mutation was randomly recognized in primary CRC or metastatic liver among four cases involving synchronous liver metastasis (Figs. 1c and 2).
K-ras mutational status is a critical determinant in identifying patients who are likely to benefit from cetuximab or panitumumab, anti-EGFR antibody treatments; therefore, this discrepancy between primary CRC and metastatic liver was a critical problem. For each patient with a metachronous liver metastasis, K-ras was mutant in the liver metastasis despite a wild-type K-ras in the primary CRC (Figs. 1b  and 2 ). In contrast, the K-ras mutational pattern was random (mutation/wild in primary and metastatic liver, n = 2; and wild/ mutation, n = 2) for cases involving synchronous liver metastases (Fig. 2) . This finding may indicate that K-ras mutation is not critical in the development of synchronous liver metastasis.
Prognostic analysis of K-ras mutation status in cases of recurrent CRC involving liver metastasis
Next, we examined whether K-ras mutational status was associated with prognosis. Patients who received cetuximab for treatment of the liver metastasis were excluded from this study. K-ras mutation status did not show prognostic stratification (Fig. 3) . Of the 43 patients, 19 (44.1%) survived for 5 years after liver resection, and any clinicopathological factor could not predict survival. None of seven factors-age, sex, primary CRC portion, histology, metastatic mode, preoperative chemotherapy, or primary cancer stage was correlated with poor prognosis after resection of the liver tumor (Table 1) . Moreover and the most importantly, K-ras mutational status was not associated with any of these clinicopathological factors (Table 2 ).
K-ras gene mutation by direct sequence and SSCP
SSCP was informative for 36 of the 43 cases. K-ras mutations were detected by SSCP more frequently than by direct sequencing. This finding was consistent with our previous observation that SSCP is a more sensitive method than direct sequence to detect K-ras mutation. For both primary CRCs and CRC-derived liver metastases, the results from the SSCP analysis of K-ras were significantly associated with those from direct sequencing (P = 0.00060 and P = 0.0038, respectively) ( Table 2) . Therefore, we think that results from direct sequencing reflected only the predominant genotype within each genetically heterogeneous tumor because direct sequencing is less sensitive than SSCP. 2 . Schema of K-ras mutation profiles in primary CRC and liver metastasis. Six cases showed K-ras mutation exclusively found only in liver metastasis, but not in primary CRC, all of which were recognized for codon 13. There is a 1-to-1 correspondence between top and bottom rows in the same patients.
Discussion
Oudejans et al. were the first to examine both primary CRCs and corresponding metastases [14] . They examined three types of mutations, those in codons 12, 13, and 61; they found that any K-ras mutation is evident in 30% of Dukes B CRC. They also investigated K-ras mutation in cases of CRC with liver metastases; mutations were evident in 50% of the cases they examined, but a mutation was not present in both the primary tumor and the metastasis in each of these cases. Specifically, a mutation was detected in the metastasis, but not in the primary tumor in some cases; in other cases, a mutation was found only in the primary tumor. These results are consistent with results from the later studies [17, 18] , and similar to results from our current study. In most cases, K-ras mutational status in the primary CRC is the same as that in the metastasis (Fig. 2) .
The novelty of our current finding was that we found a unique pattern of K-ras mutation and mutation subtypes in metachronous metastases to the liver. First, K-ras mutations exclusively found in the metastatic tumors were recognized in the metachronous cases as compared with synchronous ones. Secondly, each such mutation was always in codon 13 (Fig. 2) . As the metachronous liver tumors may have involved micrometastasis of cancer cells with a K-ras mutation [19, 20] , our clinical finding may indicate that K-ras mutations in codon 13 are required for micrometastasis to the liver. Intriguingly, Conzelmann et al. reported that lymph node specimens from corresponding carcinomas with a K-ras mutation in codon 13 have a significantly higher incidence (82%) of CEC (circulating epithelial cells) that did those from corresponding carcinomas with a K-ras mutation in codon 12 (57%, P b 0.05) or with wild-type K-ras sequences (59%, P b 0.05) [21] . This finding Fig. 3 . No prognostic relevance of clinicopathological factors in colorectal cancer (CRC) with liver metastasis after liver resection. (a) Patient prognosis according to K-ras mutation profiles of primary CRC and its corresponding liver metastasis. Group A was defined as mutant type K-ras/mutant type K-ras in the primary CRC and the corresponding liver metastasis. Group B was defined as mutant K-ras/wild type K-ras in the primary CRC and the corresponding liver metastasis. Group C was defined as mutant K-ras/mutant type K-ras in the primary CRC and the corresponding liver metastasis. Group D was defined as wild type K-ras/wild type K-ras in the primary CRC and the corresponding liver metastasis. There was no statistical differences of prognosis among the 4 groups. 
Table 2
Correlation of K-ras mutation status by SSCP and direct sequence. may be associated with development of micrometastasis of liver during CRC progression.
Phenotype changes that resulted from somatic knock-out of mutated K-ras demonstrate the bona fide relevance of K-ras gene in CRC. Shirasawa et al. made mutated K-ras knock-out with two CRC cell lines-DLD1 and HCT116-both of which constitutively harbor mutations in codon 13 [22] . Numerous in vitro functional studies demonstrate that the mutated allele of codon 13 has oncogenic properties that affected distant metastatic phenotypes [23] ; specifically, activating codon 13 mutations resulted in an angiogenic phenotype with VEGF (vascular endothelial growth factor) overexpression [24, 25] or an invasive phenotype with PAI-1 activation [26, 27] and antagonized p53 [28] .
However, there is less information about knock-out of codon 12 of K-ras in human cancer cells. Based on our present clinical data and data from earlier in vitro studies, we could not reject the published hypothesis that codon 12 accounts for most distant hematogenous deposits [17] . Nevertheless, we offer a new hypothesis; specifically, we propose that mutation of K-ras codon 13 is strongly associated with micrometastasis of CRC because of augmented metastatic properties resulting from such mutations.
In our study, either synchronous liver metastasis or the initial tumor advanced stage is likely to show poorer prognosis than otherwise cases ( Fig. 3c and d ), while this difference was not statistically significant putatively due to small number of cases examined in this study. This difference might reflect the differential molecular profiles of synchronous and metachronous liver metastasis. K-ras mutation might not be necessary for the development of synchronous liver metastasis; K-ras mutation was random in both primary and metastatic CRC, although there was limitation in small number to conclude it (Fig. 2) . Various other molecules may be involved in synchronous liver metastasis; the most compelling evidence is for PRL-3 involvement [29] [30] [31] . Our current data may provide a critical insight into the development of therapeutic strategies for treatment of recurrent CRC; specifically, our data may indicate that the best therapeutic strategies for CRC cases involving synchronous liver metastasis differ from those for cases involving metachronous liver metastasis.
K-ras mutational status is an excellent biomarker for assessing whether anti-EGFR antibodies will be effective or not [8] ; however, we have often experienced resistant responses to EGFR-inhibition therapy in cases involving a tumor with wild-type K-ras. The data presented here demonstrated that K-ras mutational status of primary CRC tumor tissue was not necessarily consistent with that of the disseminated tumor cells. Cases of resistant CRC might involve a primary CRC with wildtype K-ras and a corresponding liver metastasis with a mutation in K-ras codon 13. Our data can account, at least partially, for the clinical phenomenon that anti-EGFR monoclonal antibody is not effective against metastatic CRC with wild type K-ras in the primary tumors.
In conclusion, we investigated the K-ras mutation profiles of 43 primary CRCs and each corresponding liver metastasis. In some cases, the K-ras mutational status of the primary CRC differed from that of the liver metastasis, and codon 13 mutations may explain such discrepancies. Current data may lead to the development of personalized medicine for recurrent CRC, although a more specific validation study is still required.
